Both in Pharmaceuticals
Cue Biopharma vs ALX Oncology Holdings
Over the past year CUE returned +18.2% and ALXO returned −22.9%; their daily moves had a correlation of -0.05.
CUE +18.2% ALXO −22.9%Growth of $1, one year, split-adjusted
| Metric | CUE | ALXO |
|---|---|---|
| Price | $25.51 | $1.35 |
| Market cap | $185.3M | $186.7M |
| Today | −7.07% | −2.88% |
| 1 month | −8.5% | −32.5% |
| 6 months | +276.3% | −29.3% |
| Year to date | +178.4% | +19.5% |
| 1 year | +19.8% | −27.8% |
| Revenue growth (YoY) | +166.7% | — |
| Gross margin | 100.0% | — |
| Net margin | −1943.2% | — |
| P/E (TTM) | — | — |
| Price / sales | 4.9× | — |
| Net cash | $16.4M | $128.5M |
| Dividend yield | — | — |
| Volatility (60d) | 125.7% | 66.1% |
| Short % of float | 9.4% | 6.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).